Body Iron Stores , Infection , and Risk of Acute Myocardial Infarction

Myocardial Infarction To the Editor: Tuomainen et al 1 have noted an association between increased iron stores, as measured by a reduced ratio of serum transferrin receptor concentration to serum ferritin concentration, and excess risk of acute myocardial infarction (AMI). It has been suggested that iron can catalyze toxic redox reactions, which may lead to an increased risk for coronary heart disease and AMI. Another mechanism by which iron might increase the risk of AMI involves a possible role for iron in facilitating some infections. Vertebrates have a hypoferremic response during infection that lowers the presence of iron as serum transferrin, temporarily storing the metal as ferritin. Intestinal absorption of iron also declines during infection. Bacterial mechanisms to obtain iron from a host include direct uptake of iron from the labile iron pool, siderophore-mediated iron uptake, and iron uptake by direct interaction with transferrin, lactoferrin, or hemecontaining proteins. Various mechanisms by which infectious processes might induce atherogenesis have been proposed, including cytopathic effects of infection on endothelial and smooth muscle cells, formation of circulating toxins or immune complexes that deposit on vessel walls, elicitation of an inflammatory response, induction of alterations of serum prostaglandin and lipid metabolism, or elicitation of a hypercoagulable state that increases the risk of thrombosis. Recent research has suggested that numerous organisms may be associated with an increased risk of AMI. These include Helicobacter pylori, Chlamydia pneumoniae, herpes simplex virus, and cytomegalovirus. 2

[1]  P. Ridker,et al.  Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. , 1998, Circulation.

[2]  Y. Nishizawa,et al.  1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. , 1998, Circulation.

[3]  I. Pörsti,et al.  Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. , 1998, Pharmacology & toxicology.

[4]  M. Komajda,et al.  Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. , 1998, European heart journal.

[5]  C. Fahrenbruch,et al.  Circadian variations in the occurrence of cardiac arrests: initial and repeat episodes. , 1998, Circulation.

[6]  M. Komajda,et al.  Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. , 1998, Circulation.

[7]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[8]  J. Salonen Excessive intake of iron and mercury in cardiovascular disease. , 1998, Bibliotheca nutritio et dieta.

[9]  J. Raulston Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins , 1997, Infection and immunity.

[10]  J. Manson,et al.  Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. , 1997, Circulation.

[11]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[12]  M. Komajda,et al.  The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. , 1997, Journal of molecular and cellular cardiology.

[13]  V. Fuster,et al.  Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. , 1996, Circulation.

[14]  T. Imaizumi,et al.  Disappearance of giant negative T waves in patients with the Japanese form of apical hypertrophy. , 1995, Journal of the American College of Cardiology.

[15]  L. Demer A skeleton in the atherosclerosis closet. , 1995, Circulation.

[16]  P. Brugada,et al.  At what time are implantable defibrillator shocks delivered? Evidence for individual circadian variance in sudden cardiac death. , 1995, European heart journal.

[17]  M. Josephson,et al.  Sudden cardiac death, circadian rhythms and defibrillators. , 1995, European heart journal.

[18]  D. Bagchi,et al.  Oxidative mechanisms in the toxicity of metal ions. , 1995, Free radical biology & medicine.

[19]  H. Leclerc,et al.  Iron acquisition by Helicobacter pylori: importance of human lactoferrin , 1993, Infection and immunity.

[20]  D. Kramsch Calcium antagonists and atherosclerosis. , 1985, Advances in experimental medicine and biology.

[21]  D. Kramsch,et al.  Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids. , 1981, Science.